Watch for regulatory submission timelines and potential accelerated approval pathways in PROC. The October 28 investor update may provide additional details on filing strategy and commercial opportunity sizing. Monitor for data presentations at future medical meetings and expansion into other Rina-S Phase 3 trials (endometrial, PSOC maintenance, first-line ovarian).
Price Chart
Executive Summary
Genmab announced positive topline Phase 3 RAINFOL-02 results for Rina-S in platinum-resistant ovarian cancer, meeting both PFS and OS endpoints with highly statistically significant hazard ratios (PFS HR 0.29, OS HR 0.43 in ITT). This is the first Phase 3 readout for the Rina-S program and represents a major pipeline catalyst, supporting regulatory discussions and potential label expansion across FR expression levels.
Key Facts
- Phase 3 RAINFOL-02 met primary endpoint PFS and key secondary endpoint OS in platinum-resistant ovarian cancer
- ITT population (N=584): 71% reduction in risk of progression or death (HR 0.29, 95% CI 0.23-0.37, p<0.0001)
- ITT population OS: 57% reduction in risk of death (HR 0.43, 95% CI 0.31-0.59, p<0.0001)
- PAS population (N=492): 67% PFS risk reduction (HR 0.33, 95% CI 0.26-0.42, p<0.0001) and 56% OS risk reduction (HR 0.44, 95% CI 0.31-0.63, p<0.0001)
- Safety profile consistent with known profile of Rina-S, no new safety signals
- Genmab plans to engage with regulatory authorities worldwide regarding potential next steps
- Rina-S is being evaluated in five Phase 3 trials across multiple gynecologic cancers and other solid tumors
- Investor update scheduled for October 28, 2026
Financial Impact
No financial figures provided in filing. Rina-S is wholly owned by Genmab; positive Phase 3 data supports potential multi-billion-dollar peak sales opportunity in ovarian cancer and beyond, pending regulatory approvals.
Risk Factors
- Regulatory approval is not guaranteed despite positive data
- Competition from other FRα-targeted therapies (e.g., mirvetuximab) and emerging ADCs
- Manufacturing scale-up and commercial launch execution risks
- Payer reimbursement dynamics in PROC
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000138 |
| Document: gmab_20261023x6k.htm | 0001434265-26-000138 |
| Document: 0001434265-26-000138-index-headers.html | 0001434265-26-000138 |
| Document: 0001434265-26-000138-index.html | 0001434265-26-000138 |
| Document: 0001434265-26-000138.txt | 0001434265-26-000138 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | 6-K | $42.64 | awaiting T+1 | — | $43.79 (+2.70%) |
Oct 13, 2026 13d ago | 6-K | $36.57 $36.89 | ▲ +0.88% | ▲ +1.96% | $43.79 (+19.74%) |
Oct 7, 2026 18d ago | 6-K | $36.65 $36.05 | ▼ −1.64% | ▼ −1.21% | $43.79 (+19.48%) |
Oct 5, 2026 20d ago | SC 13G | $37.80 $36.65 | ▼ −3.04% | ▼ −2.80% | $43.79 (+15.85%) |
Oct 5, 2026 20d ago | 6-K | $38.48 $37.80 | ▼ −1.77% | ▼ −2.32% | $43.79 (+13.80%) |
Oct 2, 2026 23d ago | 6-K | $34.75 $38.48 | ▲ +10.73% | ▲ +10.06% | $43.79 (+26.01%) |
Sep 29, 2026 26d ago | 6-K | $35.57 $35.68 | ▲ +0.30% | ▲ +0.50% | $43.79 (+23.11%) |
Sep 24, 2026 4w ago | 6-K | $34.83 $35.32 | ▲ +1.41% | ▲ +0.86% | $43.79 (+25.72%) |
Sep 8, 2026 6w ago | 6-K | $33.53 $33.04 | ▼ −1.46% | ▼ −1.00% | $43.79 (+30.60%) |
Aug 12, 2026 10w ago | 6-K | $31.42 $31.34 | ▼ −0.25% | ▼ −0.95% | $43.79 (+39.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers